BioNTech SE

Youtube Subscribe

Open: 89.7 Close: 90.94 Change: 1.24

You're running out of time to find out about BioNTech SE using an AI.

This document will help you to evaluate BioNTech SE without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about BioNTech SE are: SE, BioNTech, security, loss, shareholder, action, March, …

Concept Map

Semantic Network

Stock Summary

BioNTech SE develops and commercializes immunotherapies for cancer and other infectious diseases. FixVac product candidates are in Phase II clinical trials for advanced melanoma, including BNT111, BNT112, BN111.

Today's Summary

Accesswire lost money on BioNTech SE (BNTX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky. BioNTec SE ADr shed 2.70% to $88.96 Thursday.

Today's News

biontech se adr falls thursday, underperforms market - marketwatch.com. BioNTech SE ADR shed 2.70% to $88.96 Thursday, on what proved to be an all-around great trading session. Accesswire lost money on BioNTech SE (BNTX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky. If you suffered a loss on your BioNTec SE (NASDAQ:BNTx) investment and want to learn about a potential recovery under the federal securities laws, foll... 2 days ago - Accesswire BNTX Investors Have Opportunity to Lead BioNTch SE Securities Levi & Korsinsky reminds shareholders of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 12, 2024 in BioNTech SE Lawsuit. If you suffered a loss on your BioNTec SE (NASDAQ:BNTX) investment and want to learn about a potential recovery under the federal securities laws. Pomerantz Law Firm reminds shareholders with losses on their investment in biontech se of class action lawsuit and upcoming deadlines – bntx. shareholder alert: pomerantz law firm reminds shareholders. Shareholders with losses are urged to ask the Court. Bronstein, Gewirtz & Grossman LLC announces that BioNTech SE Investors with substantial losses have opportunity to lead class action lawsuit. The lawsuit seeks to recover damages against Defendants for alleged violations of federal securities laws. A securities class action lawsuit has been filed against BioNTech SE (BioNTech) (NASDAQ:BNTX) The action charges the company with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the companys business, operations, and prospects. Contact The Gross Law Firm before March 12, 2024. BioNTech SE Sued for Securities Law Violations - Contact The Gross Law Firm Before March 12, 2024 to Discuss Your Rights – BNTX. A class action securities lawsuit was filed against BioNTech SE that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between March 30, 2022 and October 13, 2023. The Gross Law Firm issues the following notice to shareholders. A class action securities lawsuit was filed against BioNTech SE that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between March 30, 2022 and October 13, 2023. Investors should contact Levi & Korsinsky before March 12, 2024 to discuss your rights. bntx deadline notice: rosen, a leading national firm, encourages biontech se investors with losses in excess of $100k to secure counsel before important march 12 deadline in securities class action. BNTX share price is $88.88, which is 68% below its historic value. BioNTech SE stock price is 88.96 USD today. Analysts estimate an earnings decrease this quarter of $0.12 per share, a decrease next quarter of$0.00 per share. The average price target is $137.14, which is 5080% higher than the current price. The BioNTech SE ADR BNTX slipped 1.47% to $91.43 Wednesday, on what proved to be an all-around grim trading session for the stock market. BioNTec SE ADr closed $45.49 below its 52-week high ($136.92)

Stock Profile

"BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany."

Keywords

Are looking for the most relevant information about BioNTech SE? Investor spend a lot of time searching for information to make investment decisions in BioNTech SE. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about BioNTech SE are: SE, BioNTech, security, loss, shareholder, action, March, and the most common words in the summary are: biontech, news, weather, ago, stock, se, class, . One of the sentences in the summary was: BioNTec SE ADr shed 2.70% to $88.96 Thursday.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #biontech #news #weather #ago #stock #se #class.

Read more →

Youtube Subscribe

---